Transcription factor c-Myb promotes the invasion of hepatocellular carcinoma cells via increasing osteopontin expression

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Chen, Rong Xin ^a   Xia, Yun Hong ^a   Xue, Tong Chun ^a   Ye, Sheng Long ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OLIGONUCLEOTIDE; OSTEOPONTIN; PHOSPHOPROTEIN; PROTEIN C MYB; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; DNA MICROARRAY; DOWN REGULATION; ELECTROPHORETIC MOBILITY; EMBRYO; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; METASTASIS; ONCOGENE C MYB; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY MECHANISM; UPREGULATION; BIOSYNTHESIS; CANCER INVASION; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPONTIN; PROTO-ONCOGENE PROTEINS C-MYB;

EID: 78650611349     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-172     Document Type: Article

References (33)

1. Global cancer statistics, 2002. DM Parkin F Bray J Ferlay P Pisani, CA Cancer J Clin 2005 55 74 108 10.3322/canjclin.55.2.74 15761078
2. Hepatocellular carcinoma. JM Llovet A Burroughs J Bruix, Lancet 2003 362 1907 1917 10.1016/S0140-6736(03)14964-1 14667750
3. A decade's studies on metastasis of hepatocellular carcinoma. ZY Tang SL Ye YK Liu LX Qin HC Sun QH Ye L Wang J Zhou SJ Qiu Y Li,, et al. J Cancer Res Clin Oncol 2004 130 187 196 10.1007/s00432-003-0511-1 14685850
4. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. D Coppola M Szabo D Boulware P Muraca M Alsarraj AF Chambers TJ Yeatman, Clin Cancer Res 2004 10 184 190 10.1158/1078-0432.CCR-1405-2 14734468
5. Osteopontin: role in cell signaling and cancer progression. H Rangaswami A Bulbule GC Kundu, Trends Cell Biol 2006 16 79 87 10.1016/j.tcb.2005.12.005 16406521
6. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. QH Ye LX Qin M Forgues P He JW Kim AC Peng R Simon Y Li AI Robles Y Chen,, et al. Nat Med 2003 9 416 423 10.1038/nm843 12640447
7. Osteopontin expression and prognostic significance in non-small cell lung cancer. V Donati L Boldrini M Dell'Omodarme MC Prati P Faviana T Camacci M Lucchi A Mussi M Santoro F Basolo G Fontanini, Clin Cancer Res 2005 11 6459 6465 10.1158/1078-0432.CCR-05-0541 16166420 (Pubitemid 41338982)
8. Role of osteopontin in breast cancer patients. A Macri A Versaci G Lupo G Trimarchi C Tomasello S Loddo G Sfuncia R Caminiti D Teti C Famulari, Tumori 2009 95 48 52 19366056
9. Osteopontin and colon cancer progression. TJ Yeatman AF Chambers, Clin Exp Metastasis 2003 20 85 90 10.1023/A:1022502805474 12650611
10. Transcription factor-mediated epigenetic regulation of cell growth and phenotype for biological control and cancer. GS Stein JL Stein AJ Van Wijnen JB Lian M Montecino CM Croce JY Choi SA Ali S Pande MQ Hassan,, et al. Adv Enzyme Regul 50 160 167 10.1016/j.advenzreg.2009.10.026 19896493
11. Transcription factor AP-1 promotes growth and radioresistance in prostate cancer cells. R Kajanne P Miettinen M Tenhunen S Leppa, Int J Oncol 2009 35 1175 1182 19787273
12. Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1-independent mechanism. Y Song J Wu RA Oyesanya Z Lee A Mukherjee X Fang, Clin Cancer Res 2009 15 492 501 10.1158/1078-0432.CCR-08- 1945 19147754
13. The RUNX genes: gain or loss of function in cancer. K Blyth ER Cameron JC Neil, Nat Rev Cancer 2005 5 376 387 10.1038/nrc1607 15864279
14. Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics. Y Li B Tian J Yang L Zhao X Wu SL Ye YK Liu ZY Tang, J Cancer Res Clin Oncol 2004 130 460 468 10.1007/s00432-004-0564-9 15146329
15. HIV-1-Tat protein activates phosphatidylinositol 3-kinase/AKT-dependent survival pathways in Kaposi's sarcoma cells. MC Deregibus V Cantaluppi S Doublier MF Brizzi I Deambrosis A Albini G Camussi, J Biol Chem 2002 277 25195 25202 10.1074/jbc.M200921200 11994280
16. Cloning and characterization of the human osteopontin gene and its promoter. N Hijiya M Setoguchi K Matsuura Y Higuchi S Akizuki S Yamamoto, Biochem J 1994 303 Pt 1 255 262 7945249
17. Osteopontin: An Effector and an Effect of Tumor Metastasis. LA Shevde S Das DW Clark RS Samant, Curr Mol Med 2010 10 1 71 81 10.2174/156652410791065381 20205680
18. Osteopontin as a target for cancer therapy. NI Johnston VK Gunasekharan A Ravindranath C O'Connell PG Johnston MK El-Tanani, Front Biosci 2008 13 4361 4372 10.2741/3009 18508515
19. Osteopontin: an emerging therapeutic target for anticancer therapy. S Jain G Chakraborty A Bulbule R Kaur GC Kundu, Expert Opin Ther Targets 2007 11 81 90 10.1517/14728222.11.1.81 17150036
20. Osteopontin: regulation in tumor metastasis. PY Wai PC Kuo, Cancer Metastasis Rev 2008 27 103 118 10.1007/s10555-007-9104-9 18049863
21. The functional -443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor. J Schultz P Lorenz SM Ibrahim G Kundt G Gross M Kunz, Mol Carcinog 2009 48 14 23 10.1002/mc.20452 18459127
22. MYB function in normal and cancer cells. RG Ramsay TJ Gonda, Nat Rev Cancer 2008 8 523 534 10.1038/nrc2439 18574464
23. c-Myb a stem-progenitor cell regulator in multiple tissue compartments. RG Ramsay, Growth Factors 2005 23 253 261 10.1080/08977190500233730 16338788
24. Role of c-Myb during prolactin-induced signal transducer and activator of transcription 5a signaling in breast cancer cells. F Fang MA Rycyzyn CV Clevenger, Endocrinology 2009 150 1597 1606 10.1210/en.2008-1079 19036881
25. Cyclooxygenase-2, a colorectal cancer nonsteroidal anti-inflammatory drug target, is regulated by c-MYB. RG Ramsay A Friend Y Vizantios R Freeman C Sicurella F Hammett J Armes D Venter, Cancer Res 2000 60 1805 1809 10766162
26. c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. A Biroccio B Benassi I D'Agnano C D'Angelo S Buglioni M Mottolese A Ricciotti G Citro M Cosimelli RG Ramsay,, et al. Am J Pathol 2001 158 1289 1299 11290547
27. Activation of c-MYC and c-MYB proto-oncogenes is associated with decreased apoptosis in tumor colon progression. C Greco S Alvino S Buglioni D Assisi R Lapenta A Grassi V Stigliano M Mottolese V Casale, Anticancer Res 2001 21 3185 3192 11848471
28. The role of c-Myb and Sp1 in the up-regulation of methionine adenosyltransferase 2A gene expression in human hepatocellular carcinoma. H Yang ZZ Huang J Wang SC Lu, FASEB J 2001 15 1507 1516 10.1096/fj.01-0040com 11427482 (Pubitemid 32673380)
29. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. G Chakraborty S Jain R Behera M Ahmed P Sharma V Kumar GC Kundu, Curr Mol Med 2006 6 819 830 10.2174/156652406779010803 17168734
30. Phenotypic transcription factors epigenetically mediate cell growth control. SA Ali SK Zaidi CS Dacwag N Salma DW Young AR Shakoori MA Montecino JB Lian AJ van Wijnen AN Imbalzano,, et al. Proc Natl Acad Sci USA 2008 105 6632 6637 10.1073/pnas.0800970105 18445650
31. Antisense oligodeoxynucleotide directed against c-myb has anticancer activity and potentiates the antiproliferative effect of conventional anticancer drugs acting by different mechanisms in human colorectal cancer cells. MS Abaza RJ Al-Attiyah AM Al-Saffar SM Al-Sawan NM Moussa, Tumour Biol 2003 24 241 257 10.1159/000076139 15001837
32. Targeting c-Myb expression in human disease. RG Ramsay AL Barton TJ Gonda, Expert Opin Ther Targets 2003 7 235 248 10.1517/14728222.7.2.235 12667100
33. Use of c-myb antisense oligonucleotides to increase the sensitivity of human colon cancer cells to cisplatin. T Funato J Satou K Kozawa S Fujimaki T Miura M Kaku, Oncol Rep 2001 8 807 810 11410788